Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

Board of Directors of Sistema recommended that dividends be paid for 2022

5/25/23 AFKS

Rosseti Center reported for 3 months of 2023 by IFRS

5/25/23 MRKC

Board of Directors of Saratov oil refinery plant recommended that dividends be paid for 2022

5/25/23 KRKN

Rosseti Center and Volga Region reported 3 months of 2023 by IFRS

5/25/23 MRKP

Evoqua combines with Xylem

5/25/23 AQUA

Xylem has teamed up with Evoqua

5/25/23 XYL

Noventiq receipts on Moscow Exchange can be exchanged for shares of Softline JSC

5/25/23 SOFL

Noventiq receipts on Moscow Exchange can be exchanged for shares of Softline JSC

5/25/23 SFTL

NVIDIA reported for 3 months of fiscal year 2024

5/25/23 NVDA

TCS Group reported for 3 months of 2023

5/24/23 T